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http://dx.doi.org/10.1016/j.hkjn.201Summary Chronic kidney disease (CKD) is known to be the hallmark with fibrosis and inflam-
mation that leads to end stage renal disease. Since the discovery over 2 decades ago of trans-
forming growth factor (TGF)-b as a key mediator in CKD, studies of TGF-b signaling in the
kidney have focused on fibrosis and inflammation. TGF-b exerts its cellular effect via Smad2
and Smad3 after binding to its receptors. Smad7, as an inhibitory Smad, provides a negative feed-
back loop to limit TGF-b action for maintaining homeostasis. Recently, the precise roles of indi-
vidual Smads and receptors have been further characterized and the results reveal the
complexity of TGF-b signaling during CKD. Although Smad3 plays a pathogenic role in CKD, Smad2
and Smad7 are protective. Furthermore, Smad4 enhances Smad3-mediated renal fibrosis as well
as suppresses nuclear factorekB-driven renal inflammation in a Smad7-dependent manner.
Emerging evidence demonstrates the ability of TGF-b/Smad3 signaling to regulate specific mi-
croRNAs, revealing that microRNAs are critical downstream effectors of TGF-b/Smad3 signaling
in renal fibrosis and inflammation. Recent studies in animal models of kidney disease demon-
strate the therapeutic potential of microRNA therapy, Smad3 inhibitor, and Smad7 agonist in
CKD. Because the accumulation of extracellular matrix and infiltration of inflammatory cells,
which are the major pathological consequences of CKD, are due to activation of TGF-b/Smad3
signaling pathways, targeting the downstream TGF-b/Smad3 signaling pathway by gene transfer
of either Smad7 or Smad3-dependent microRNAs, and by applying Smad3 inhibitor and Smad7
agonist may offer a specific and effective therapeutic strategy for kidney disease.
纖維化及炎癥是慢性腎病(CKD)的主要病理變化，最終導致終末期腎病。自從在二十多年前TGF-b
被發現為CKD的關鍵中介物起，腎臟TGF-b訊息傳遞的相關研究便著眼於纖維化及炎癥方面。TGF-
b在與受體結合後，透過Smad2及Smad3以產生細胞效應。具抑制性的Smad7可透過負回饋機制，Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin,
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TGF-b signaling during kidney diseases 15以限制TGF-b的作用，從而維持平衡狀態。近年的研究更確認了個別Smads及受體的具體角色，顯
示了CKD的TGF-b訊息傳遞複雜性。Smad3在CKD中具有致病角色，Smad2及Smad7則具保護性。再
者，Smad4可促進Smad3介導的腎纖維化，并通過Smad7依賴的方式抑制NF-kB介導的腎臟炎癥。
新證據更顯示，TGF-b/Smad3訊息傳遞具調節特定microRNAs的能力，意味著microRNAs在腎纖維
化及炎癥的TGF-b/Smad3訊息傳遞中是重要的下游效應物。近年關於腎病的動物實驗更發現，mi-
croRNA療法、Smad3抑制劑、及Smad7作用劑對CKD具潛在療效。有鑑於CKD的主要病理變化，如
細胞外基質(ECM)的積聚及炎性細胞的浸潤，乃歸因於TGF-b/Smad3訊息傳遞途徑的活化，我們可
以透過Smad7-或Smad3-倚賴性microRNAs的基因轉移、及採用Smad3抑制劑或Smad7作用劑等，對
TGF-b/Smad3的下游訊息傳遞途徑作出干預，從而為腎病患者提供一個特定且有效的治療方案。Introduction
Chronic kidney disease (CKD) is a condition characterized by
a gradual loss of kidney function over time because of renal
tissue injury and nephron loss. Eventually, CKD can lead to
end-stage renal diseases. The patients may die due to sec-
ondary events, such as cardiovascular failure. The incidence
of CKD is rising worldwide as the population pertension and
diabetes increase in prevalence. Thus, CKD represents a
significant human, clinical, and socioeconomic burden.
Regardless of etiology, typical pathological phenotypes of
CKD include fibrosis, infiltration of inflammatory cells, and
nephron atrophy. Over 2 decades of studies have demon-
strated a critical role for the cytokine transforming growth
factor (TGF)-b as a key mediator of these pathological phe-
notypes. TGF-b contains three isoforms (TGF-b1, 2, and 3)
that are pleiotropic cell signaling molecules involved in em-
bryonic development and the regulation of tissue homeo-
stasis.1e3 Among these isoforms, TGF-b1 is the central
mediator in the fibrogenic process.1 TGF-b1 exerts its
cellular effect via Smad2 and Smad3, after binding to TGF-b
receptors II and I (TbRII and TbRI). Upon ligand binding,
phosphorylated TbRII activates TbRI by phosphorylation.
TbRI subsequently activates Smad2 and Smad3, which
consequently interactwith Smad4.Thus, anactive Smad2/3/
4 complex is formed and this translocates to the nucleus to
regulate the target gene transcription.2 As an inhibitory
Smad, Smad7 induces TbRI and Smads degradation via the
ubiquitin proteasome degradation mechanisms4,5 to main-
tain homeostasis. By contrast, Smad7 is also capable of
inducing IkBa to suppress nuclear factor (NF)ekB-driven in-
flammatory response (Fig. 1). In addition to TGF-b, advanced
glycation end-products (AGEs), high glucose, angiotensin II
(AngII) are also able to activate Smad signaling via mitogen-
activated protein kinase (MAPK) to induce kidney injury.
Recent studies demonstrate that microRNAs may be
downstream mediators of TGF-b/Smad3 signaling during
CKD. Thus, targeting TGF-b/Smad3 specific microRNAs could
be an effective alternative to treat kidney disease. Studies of
asiatic acid, a Smad7 agonist, and Smad3 inhibitor also reveal
a possible therapeutic potential of these compounds.
Role of TGF-b signaling in kidney diseases
Fibrosis
TGF-b/Smad signaling
Tubulointerstitial fibrosis and glomerulosclerosis are
regarded as a central event in the progression of CKDregardless of etiology. These two pathological events lead
to glomerular and tubular malfunction and degeneration as
an excessive accumulation and deposition of extracellular
matrix (ECM) components occurs within renal tubules and
glomeruli. TGF-b is widely recognized as a strong inducer of
fibrosis in renal structures during CKD because it can in-
crease ECM production and alter the degradation of ECM
components.3 Studies from both in human and experi-
mental kidney diseases confirm that TGF-b1 is highly
upregulated in the fibrotic kidney.6,7 The role of TGF-b1 in
renal fibrosis has extensively reviewed6,8e10 and now we
will focus on the recent findings of TGF-b signaling in
fibrosis.
Upon TGF-b binding, TbRII binds to TbRI to form a stable
complex. TbRII then activates TbRI via phosphorylation.
The activated TbRI receptor thus phosphorylates Smad2
and Smad3 at C-terminal serines. Receptor phosphorylation
activates TGF-b-induced signaling and provides the basis for
the roles of TbRII and TbRI kinases as signal transducers.
TbRI has also been reported to participate in the path-
ogenesis of experimental intestinal fibrosis.11 During in-
testinal fibrosis, TbRI and intestinal wall collagen
deposition are upregulated in experimental animal models
but these effects are suppressed after treatment with a
TbRI inhibitor, SD-208. Although TGF-b1 induces gene
expression of TbRI and collagen 1 in isolated myofibro-
blasts, knockdown of TbRI expression by siRNA and treat-
ment with SD-208 abolish these effects.
Conditionally deleting TbRII in tubular epithelial cells of
a mouse model of unilateral ureteral obstruction (UUO)
inhibits severe tubulointerstitial fibrosis in the UUO kid-
neys.12 This inhibition is associated with the impairment of
TGF-b/Smad3 signaling but not with the ERK/p38 MAP ki-
nase pathway. Similarly, in vitro disruption of TbRII from
kidney fibroblasts or tubular epithelial cells suppresses
TGF-b1-induced Smad signaling and fibrosis. Thus, TbRII
plays an important role in regulating renal fibrosis.
Impairing TGF-b/Smad3, but not the noncanonical TGF-b
signaling pathway, is the key mechanism by which disrup-
tion of TbRII protects against renal fibrosis.
Smad2 and Smad3 are known to be two critical down-
stream mediators responsible for the biological effects of
TGF-b1. Activation of Smad2 and Smad3 are also signifi-
cantly increased in both experimental and human kidney
diseases, such as obstructive kidney diseases, 13e17 remnant
kidney disease,18,19 hypertensive nephropathy,20 diabetic
nephropathy 21e25 and chronic aristolochic acid nephropa-
thy.26 However, only Smad327,28 can directly bind to the
specific DNA sequences, called Smad binding element; in
the promoters of TGF-b target genes such as collagen
Figure 1 Transforming growth factor (TGF)-b/Smads and its cross-talk pathways in renal fibrosis and inflammation. After binding
with TGF-b1, TGF-b receptor II activates TGF-b receptor I kinase, which phosphorylates Smad2 and Smad3. Phosphorylated Smad 2
and Smad3 then form a complex with Smad4, which translocates into the nucleus to induce the target gene transcription, such as
microRNAs and Smad7. As an inhibitory Smad, Smad7 inhibits TGF-b/Smad3-dependent fibrosis and suppresses nuclear factorekB-
driven inflammatory response by upregulating nuclear factor of k light polypeptide gene enhancer in B cells inhibitor, alpha (IkBa).
In addition, advanced glycation end-products and angiotensin II are able to directly activate Smad3 via the ERK/p38/mitogen-
activated protein kinase (MAPK) cross-talk pathway.
16 R. Li et al.(ColIa2), tissue inhibitor of matrix metalloproteinase-1
(TIMP-1)29 and Smad 7, suggesting a pathologic role for
Smad3 in fibrosis. This critical role of TGF-b/Smad3
signaling during renal fibrosis is further confirmed by the
findings that fibrosis is alleviated in employing Smad3
knockout (KO) in mouse models of diabetic nephropathy,21
obstructive nephropathy,11 and chronic aristolochic acid
nephropathy.26
Active Smad2also formsa complexwith Smad4but its role
in fibrosis has not been widely explored because deletion of
Smad2 gene inmice causes embryonic lethality.30 However, a
recent study shows that deletionof Smad2 geneconditionally
from the kidney tubular epithelial cells significantly pro-
motes fibrosis in response to UUO.31 Knockdown of Smad2
expression in tubular epithelial cells in vitro also induces
expression of collagen I, collagen III, and TIMP-1 but reduces
expressionof thematrix-degradingenzymeMMP-2afterTGF-
b1 treatment. By contrast, overexpression of Smad2 inhibits
TGF-b1-induced Smad3 phosphorylation and collagen Imatrix expression. Smad2 deletion enhances TGF-b/Smad3
signaling and fibrosis because deletion of Smad2 elevates
Smad3 phosphorylation, nuclear translocation, promoter
activity, binding of Smad3 to a collagen promoter (Col1a2),
and autoinduction of TGF-b1.31 In conclusion, Smad3
signaling promotes renal fibrosis whereas Smad2 protects
against TGF-b-mediated fibrosis by counteracting TGF-b/
Smad3 signaling.
Smad4 is known as the common Smad in TGF-b/Smad
signaling but its functional role in TGFeb1-driven renal
fibrosis remains largely unclear. This may be largely asso-
ciated with the lethality of Smad4 KO mice.32 A recent
study shows that conditionally deletion of Smad4 inhibits
renal fibrosis and TGFeb1-induced collagen I expression in
fibroblasts.33 The mechanism of how deletion of Smad4
inhibits renal fibrosis is not attributed to the failure to
activate Smad3 phosphorylation and nuclear translocation
but to reduce the Smad3-mediated promoter activities and
the binding of Smad3 to the Col1a2 promoter.33
TGF-b signaling during kidney diseases 17Owing to the presence of a Smad binding element in the
Smad7 promoter,34e36 TGF-b rapidly induces Smad7
expression37 as a safeguard mechanism to prevent pro-
longed activation of TGF-b signaling. In CKD, Smad7 mRNA
expression is increased, and Smad7 protein is reduced
despite the upregulation of renal TGF-b1 and high levels of
activated Smad2/3.38 The reduction of Smad7 protein in
diseased kidney is attributed to the activation of Smurfs
and arkadia-dependent ubiquitineproteasome pathways
which degrade Smad7 protein via a post-transcriptional
modification mechanism.4,18,39,40 E3 ubiquitin ligases,
termed Smurf1, Smurf2, and arkadia have been shown to
physically interact with Smad7.40,41 After recruitment of
the Smad7eE3 ubiquitin ligases complex to the activated
TGF-b receptors, E3 ubiquitin ligases induce their degra-
dation through the proteasomal-ubiquitin degradation
pathways.4,5,39e41 Thus, aberrant expression of this intra-
cellular regulator of TGF-b/Smad signaling, Smad7, results
in promoting further activation of TGF-b/Smad signaling
and progressive renal fibrosis as confirmed in various rodent
models of kidney diseases.17,18,40,42,43 This is further evi-
denced in Smad7 KO mice in both UUO and diabetic models
in which more severe renal fibrosis is developed.17,25
MAPK crosstalk Increasing evidence has shown that
several factors interact with the TGFb/Smad signaling.
Physical interactions of Smad3 allow signal crosstalk with
other signaling pathways, such as the MAPK signaling
pathway, which also plays a role in the pathophysiological
processes of kidney diseases. In the context of renal
fibrosis, Smad3, without TGF-b activation, can interact with
MAPKs during AGE or AngII-mediated fibrotic response. In
diabetic conditions, AGE is capable of activating Smad 2/3
both in vivo and in vitro via the ERK/p38 MAPK-dependent
mechanism.21 Similarly, under hypertensive conditions,
Smad3 signaling is activated by AngII via the AT1 receptor-
mediated, ERK/p38 MAPK-Smad crosstalk pathway, in
addition to the TGFeb-dependent mechanism.20,44
Furthermore, both AGEs and AngII are able to activate
Smad2/3 to stimulate connective tissue growth factor
(CTGF) expression in kidney cells lacking the TGF-b1 gene
or TbRII, but not in those with blockade of MAPK signaling
by specific inhibitors, or dominant negative adenovirus to
ERK1/2 and p38.22,44 The identification of TGF-b-indepen-
dent Smad pathways has advanced our understanding of
complicated Smad signaling under disease conditions.MicroRNAs
Recent research intomicroRNAs has demonstrated that TGF-
b regulates several specific microRNAs (miRs) to control
fibrogenesis in renal disease. TGF-b1 is able to upregulate
miR-21, miR-192, miR-216a, and miR-377, but downregulate
the miR-29 and miR-200 families (Table 1).45e47 These
microRNAs play significant roles as downstream effectors in
TGFeb-induced renal fibrosis. Both miR-192 and miR-21 play
a pathological role in kidney injury and upregulation of their
expression in disease condition promotes TGFeb-induced
expression of fibrotic markers.48e51 In addition, miR-377
induces fibronectin in MCs,52 whereas miR-491-5p induces
Par-3 degradation in TECs.53MiR-382participates in TGFeb1-
induced loss of E-cadherin in human renal epithelial cells.54By contrast, members of the miR-29 and miR-200 families
play a protective role in renal injury. During renal injury,
downregulation of miR-29a and miR-29b promotes collagen
expression55,56 and reduction of miR-200a expression in
diseased condition enhances TGFeb-dependent epithelial-
to-mesenchymal transition by increasing expression of
TGF-b2 and matrix proteins.57 These findings suggest that
microRNAs play a vital role in TGF-b induced renal injury.
How TGF-b signaling regulates microRNA expression is
still underexplored. TGF-b signaling has been shown to
promote the processing of primary transcripts of miR-21
into precursor miR-21 by the Drosha complex.58 Results
from our laboratory demonstrate that the expression of
miR-21, miR-192, and the miR-29 family during renal dis-
eases are TGF-b1/Smad3 dependent.48,50,56 Smad3 medi-
ates the expression of these microRNAs by physically
interacting with Smad3-binding sites in their pro-
moters.48,49,56 Binding of Smad3 on these sites in the
promoters may either induce transcription and post-
transcriptional processing of microRNAs (such as miR-21
and miR-192) or repress the expression (such as miR-
29b).48,49,56 In addition, regulating TGF-b/Smad3-mediated
microRNAs via maintaining renal miR-29b but suppressing
miR-192 and miR-21 is another mechanism of how Smad7
protects kidneys from fibrosis.46,49
More importantly, microRNAs can also affect the TGF-b/
Smad3 signaling. Overexpression of miR-200a reduces
Smad3 activity and alleviates TGFeb1-driven fibrosis.57 In
addition, both TGF-b1 and TGF-b2 reduce miR-200a
expression in renal cells.57 This reduction is accompanied
by an increase in TGF-b2 expression because the 30UTR of
TGF-b2 is found to be a target for miR-200a. These findings
suggest a possible feedback between TGF-b2 and miR-200a.
Furthermore, downregulating Smad7 is also shown to be
one of mechanisms of how miR-21 induces fibrosis in kidney
and lung.50,59 These findings indicate critical roles of
microRNAs in TGFeb-induced renal fibrosis and the
complexity between TGF-b/Smads and microRNAs under
pathophysiological conditions.
Inflammation
It is well known that TGF-b has both profibrotic and anti-
inflammatory properties. The profibrotic role of TGF-b/
Smad signaling in renal disease has been extensively stud-
ied but the role of TGF-b/Smad signaling in renal inflam-
mation attracts little attention.
One convincing piece of evidence for the involvement of
TGF-b in inflammation is from the outcome of TGF-b1 KO
mice, which suffer from lethal inflammation and die at 3
weeks after birth.60 Furthermore, conditional deletion of
TGF-b1 or TbRII genes from T cells develops autoimmune
diseases.61,62 However, overexpressing human latent TGF-b1
in mice dampens progressive renal inflammation and fibrosis
in obstructive and immunologically-induced crescentic
glomerulonephritis.13,63,64 These findings demonstrate the
vital role of TGF-b in anti-inflammation. Recent studies show
that deletion of TbRII in kidneys impairs the anti-
inflammatory properties of TGF-b1 as evidenced by pro-
moting NF-kB signaling and proinflammatory cytokines.12
As mentioned above, TGF-b1 induces Smad7 expression
to provide a negative feedback loop by causing the
Table 1 Summary of the roles of various microRNAs during chronic kidney disease.
Treatment with
TGF-b
MicroRNA Cell type Mouse model of kidney diseases Experimental data Refs
Upregulation miR-21 TECs MCs UUO, DN in db/db mice Enhances fibrosis and inflammation 48,50
miR-192 TECs MCs UUO, STZ induced DN, DN
in db/db mice
Increases collagen deposition,
induces EMT
49,51
miR-216a MCs STZ induced DN, DN in db/db mice Increases col1a2 expression 47
miR-377 MCs Spontaneous and STZ induced DN Induces fibronectin expression 52
miR-491-5p TECs UUO (rat) Induces Par-3 degradation 53
miR-382 TEC e Suppresses E-cadherin 54
Downregulation miR-29 TECs MCs UUO Promotes collagen expression 55,56
miR-200 TECs STZ induced DN, adenine-induced Enhances EMT 57
DNZ diabetic nephropathy; EMTZ epithelial-to-mesenchymal transition; MCZ mesangial cells; STZZ streptozotocin; TECZ tubular
epithelial cells; TGF Z transforming growth factor; UUO Z unilateral ureteral obstruction.
18 R. Li et al.degradation of TbRI and Smads. Under pathological condi-
tions, reduced renal Smad7 protein not only enhances TGF-
b/Smad3-mediated renal fibrosis, but also induces renal
inflammation by activating the NF-kB-dependent inflam-
matory response.25,63 These results were confirmed by
Smad7 KO mice in the models of obstructive and diabetic
nephropathy.22,25 The activation of NF-kB/p65 along with
the levels of renal inflammatory cytokines such as inter-
leukin (IL)-1b, tumor necrosis factor-a, monocyte chemo-
tactic protein-1, intercellular adhesion molecule-1, and the
macrophage infiltration in Smad7 KO mice with diabetic
kidney disease or obstructive nephropathy are much higher
than Smad7 wild type mice.22,25 By contrast, over-
expression of Smad7 in T cells inhibits mouse crescentic
glomerulonephritis.65 In addition, Smad7 is able to directly
induce expression of IkBa, an inhibitor of NF-kB, suggesting
that TGF-b may act by inducing Smad7 to stimulate IkBa
expression for suppressing NF-kB activation.25,63
Smad4 also plays an important role in renal inflamma-
tion. Findings from our laboratory show that disruption of
Smad4 gene in kidneys results in greater infiltration of
CD45þ leukocyte and F4/80þ macrophage and elevation of
IL-1b, tumor necrosis factor-a, monocyte chemotactic
protein-1, and intercellular adhesion molecule-1 in the
ligated kidney and in IL-1b-induced macrophages.33 This
enhancement of inflammation may be due to the fact that
loss of Smad4 impairs Smad7 expression because TGF-b1
upregulates Smad7 expression via direct binding of Smad3
and Smad4 to the Smad7 promoter.34,35 The reduction of
Smad7 expression subsequently attenuates transcriptional
regulation of Smad7 to induce IkBa for the suppression of
NF-kB signaling.33
Therapeutic potential
As discussed above, TGF-b/Smad signaling plays an impor-
tant role in renal fibrosis and inflammation, therefore
blocking TGF-b signaling or targeting the downstream of
TGF-b/Smads should be effective therapeutic strategies to
treat CKD. During the past decades, targeting TGF-b with
neutralizing antibodies (such as antieTGF-b2 IgG4),66
antisense TGF-b oligodeoxynucleotides, or soluble human
TGF-b type II receptor67 ameliorate the diabetic nephrop-
athy by inhibiting renal fibrosis and reducing albuminuria.Application of specific inhibitors of TGF-b receptor kinases,
including GW788388 and IN-1130, is able to block TGF-b
signaling and reduce renal fibrosis in rodent models.68,69
However, blockade of TGF-b signaling at the upstream
levels may impair the potent anti-inflammation property of
TGF-b and subsequently promote renal inflammation.
Moreover, because of the existing intracellular Smad
crosstalk pathways, targeting TGF-b and TGF-b receptor
kinases may not be an optimal therapeutic approach.
Because the central role of Smad3 in TGF-b-induced
fibrosis and inflammation is widely recognized and the
emerging role of microRNAs in renal fibrosis is being
recognized, we thus proposed to specifically target the
downstream of TGF-b/NF-kB pathways by exploring the
therapeutic potential of Smad7 and TGF-b/Smad-depen-
dent microRNAs (Fig. 2). In the past decade, our laboratory
has developed an ultrasoundemicrobubble-mediated gene
transfer system to target genes or microRNAs specifically to
avoid the potential side-effects of virus-based gene ther-
apy. As reported recently, ultrasound-mediated transfer of
Smad7 overexpression plasmid is capable of suppressing
renal fibrosis and inflammation in a number of rodent
models including diabetes, obstructive nephropathy,
remnant kidney, and autoimmune disease.25,26,38,46 Also,
gene transfer of Smad7 is capable of protecting kidneys
from fibrosis by regulating TGF-b/Smad3-mediated renal
expression of miR-21, miR-192, and miR-29b.46 Most
recently, by using same gene transfer technique, we
demonstrate that overexpression of miR-29b or knockdown
of miR-21 in a mouse model of obstructive and diabetic
kidney diseases are capable of preventing or blocking renal
fibrosis and inflammation.46,48,50,56
Recently, studies demonstrates that a specific inhibitor
of Smad3 abrogates endothelialemesenchymal transition,
reduces renal fibrosis, and retards progression of nephrop-
athy, but does not attenuate albuminuria.70 By contrast,
asiatic acid acts as an agonist of Smad7 to inhibit liver
fibrosis by upregulating Smad7 expression.71 These novel
agents, Smad3 inhibitor and asiatic acid, may offer an
alternative treatment for renal fibrosis and inflammation.
Thus, application of microRNAs, Smad7, Smad3 inhibitor,
and Smad7 agonist in the treatment of kidney disease offers
a novel, effective, and safe therapeutic approach to com-
bat CKD.
Figure 2 Schematic diagram of current therapeutic strategies for combating chronic kidney disease by suppressing transforming
growth factor (TGF)-b-induced renal fibrosis and inflammation. These strategies include three different levels: Firstly, the sup-
pression of the upstream TGF-b signaling by employing inhibitors for TGF-b receptor kinases (including GW788388 and IN-1130),
antisense TGF-b oligodeoxynucleotides, neutralizing antibodies (antieTGF-b2 IgG4), and soluble human TbRII (sTbRII.Fc). Sec-
ondly, the blockade of Smad signaling by using Smad3 inhibitor, Smad7 agonist, and overexpression of Smad7 plasmids. Lastly the
inhibition of downstream effectors of TGF-b signaling by anti-192, antiemicroR-21, and by restoring microR-29b and microR-200.
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In general, Smad3 as a key mediator of TGF-b/Smad
signaling plays a pathogenic role in both renal inflammation
and fibrosis. Smad3 may also regulate its downstream spe-
cific microRNAs, such as miR-21, miR-192, and miR-29,
leading to involvement in renal fibrosis and inflammation by
directly interacting with Smad-binding sites in their pro-
moters. At the same time, microRNAs may regulate Smad3
activity by targeting Smad7 and TGF-b. By contrast, Smad2
is renoprotective and suppresses renal fibrosis by compet-
itively inhibiting Smad3 phosphorylation and nuclear
translocation. Smad4 plays a diverse role in promoting
Smad3-mediated renal fibrosis but suppressing NF-kB-
driven renal inflammation. Smad7 is a negative regulator of
TGF-b/Smad signaling in renal inflammation and fibrosis.
However, reduction of Smad7 protein in the diseased kidney
results in an imbalance within and between the TGF-b/
Smad and NF-kB signaling pathways to induce renal fibrosisand inflammation. Taken together, the current under-
standing of the specific role of individual Smads, TGFeb/
Smad-regulated microRNAs and the molecular mechanisms
of TGF-b/Smad-driven renal fibrosis and inflammation
should provide us valuable opportunities to search for the
better therapeutic strategy to fight kidney diseases.Acknowledgments
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